Multiple myeloma: evolving genetic events and host interactions
The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Abstract
Multiple myeloma is a neoplasm of terminally differentiated B cells (plasma cells) in which chromosome translocations frequently place oncogenes under the control of immunoglobulin enhancers. Unlike most haematopoietic cancers, multiple myeloma often has complex chromosomal abnormalities that are reminiscent of epithelial tumours. What causes full-blown myeloma? And can our molecular understanding of this common haematological malignancy be used to develop effective preventive and treatment strategies?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 40% of multiple myeloma is characterized by the presence of trisomies in the neoplastic plasma cells (hyperdiploid multiple myeloma), while most of the rest have a translocation involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 (IgH translocated multiple myeloma).38–41”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [38]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“asp?DrugCode=1%2D11465&DrugName=THALIDOMIDE+ORAL&DrugType=1">thalidomide”
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Cancer: Principles and Practice of Oncology
Gunn, W. G. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510350091047 · Cited by 1,791
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,109
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Research works printed but not linked: 6
- Jernberg-Wiklund, H. & Nilsson, K. in Human Cell Culture Vol. 3 (eds Masters, J. R. W. & Palsson, B. O.) 81–155 (Kluwer Academic, The Netherlands, 2000).
- Avet-Loiseau, H. in VIIIth International Myeloma Workshop 10–11 (Banff, Alberta, Canada, 2001).
- Epstein, J., Yaccoby, S. & Fujii, R. in VIIIth International Myeloma Workshop 21–22 (Banff, Alberta, Canada, 2001).
- Fonseca, R. et al. A molecular classification of multiple myeloma (MM), based on cytogenetic abnormalities detected by interphase FISH, is powerful in identifying discrete groups of patients with dissimilar prognosis. Blood 98, A733 (2001). · DOI · Paper page
- Stinchcombe, T. E. et al. PS-341 is active in multiple myeloma: preliminary reports of a Phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood 98, A516 (2000).
- Bergsagel, P. L. & Kuehl, W. M. in Myeloma: Biology and Management (eds Malpas, J. S., Bergsagel, D. E., Kyle, R. & Anderson, K. C.) (Oxford Univ. Press, Oxford, 1998).
Cited by
Metastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
“Anomalously, this was not the case for MMs, a malignancy of antibody-producing plasma cells (reviewed in Kuehl and Bergsagel, 2002 ), in which the DEPTOR mRNA is overexpressed (Figure 6A, Table S1).”
BackgroundSelf-citationThe molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Metadata
- Authors
- Kuehl, W. M., & Bergsagel, P. L.
- Affiliations
- National Institutes of Health (US)
- Cornell University (US)
- ORCID
- Bergsagel, P. Leif
- Venue
- Nature Reviews Cancer
- Published
- 2002-03
- Volume
- 2
- Issue
- 3
- Pages
- 175-187
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984534203
- Cited by
- 818
- References
- 164
- Citations by year
- 2026: 3 · 2025: 17 · 2024: 16 · 2023: 30 · 2022: 17 · 2021: 15 · 2020: 26 · 2019: 27 · 2018: 24 · 2017: 32 · 2016: 34 · 2015: 37 · 2014: 34 · 2013: 43 · 2012: 38
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, plasma cells, chromosomal translocation, immunoglobulin enhancer, oncogenes, chromosomal abnormalities, host-pathogen interaction, cancer prevention, myeloma treatment, B cell differentiation
- MeSH terms
- B-Lymphocytes, Enhancer Elements, Genetic, Humans, Immunoglobulins, Multiple Myeloma, Neoplasm Staging, Oncogenes, Translocation, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiple myeloma: evolving genetic events and host interactions. https://app.cochat.ai/papers/10.1038/nrc746
- The paper
- Kuehl, W. M., & Bergsagel, P. L. (2002). Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer. https://doi.org/10.1038/nrc746
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.